For Pfizer, Bigger as One May Be Better Than Smaller With Two

  • Investors, analysts say pricing climate favors bigger company
  • Pfizer pipeline promising against troubling generic landscape

For Pfizer Inc., bigger is still better. 

To continue reading this article you must be a Bloomberg Professional Service Subscriber.